Milestone Pharmaceuticals Inc (NAS:MIST)

$ 1.71 -0.04 (-2.29%) Market Cap: 91.08 Mil Enterprise Value: 54.10 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 29/100

Milestone Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Milestone Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Milestone Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Milestone Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Milestone Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Milestone Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Q2 2019 Milestone Pharmaceuticals Inc Earnings Call Transcript
Aug 13, 2019

$16.8 (+5.00%)

Earnings

Milestone Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 06:30PM GMT

Release Date Price: $3.79 (+5.87%)

Transcript

Ritu Baral

Cowen Inc., - Analyst

Joining us today for the Milestone Pharmaceuticals presentation at the 43rd Annual TD Cowen Healthcare Conference. I'm covering analyst, Ritu Baral. And here with us for Milestone is President and CEO, Joe Oliveto and Joe will be taking us through the etripamil PSVT program and the recent progress on getting it under review. Joe?

Joe Oliveto

Milestone Pharmaceuticals Inc. - President & CEO

I think [I'm miked up here, Ritu]. So, thanks again, Ritu, and thanks to all the colleagues at Cowen for having us here today and appreciate everyone in the audience for taking the time out as well as those that are online to hear the milestone story, and I will be making forward-looking statements. So, we'll direct you to our SEC filings for a full list of disclosures.

We just announced yesterday some recent news on both our PSVT program and our clinical trials in PSVT as well as regulatory guidance. Really excited to share that today from the podium. First, that we had our pre-NDA meeting with the FDA, where we proposed the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.